A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma - Trial NCT06413498
Access comprehensive clinical trial information for NCT06413498 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kite, A Gilead Company and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 450 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kite, A Gilead Company
Gilead Sciences
Timeline & Enrollment
Phase 3
Oct 01, 2024
Jul 01, 2031
Primary Outcome
Progression-Free Survival (PFS)
Summary
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel
 to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma
 who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody
 and an immunomodulatory drug.
 
 The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel
 versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per
 blinded independent review committee (IRC).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06413498
Non-Device Trial